eConsent in Medical Device Clinical Trials: FDA Part 812 IDE and ISO 14155:2026 Compliance

#1. Introduction: The Technical and Clinical Staves of Device Trials

Medical device clinical investigations differ significantly from standard pharmaceutical trials. In a drug trial, participants receive a compound and monitor side effects. In a medical device trial, participants are often asked to host an implant or operate a complex piece of hardware. This creates a dual comprehension challenge. Participants must understand the surgical procedures involved in the device placement, and they must also master the technical operation of the technology.

This dual requirement creates high stress. When a patient faces a surgical procedure (such as a pacemaker implantation or a neurostimulator placement) their ability to process complex documentation decreases. Handing a stressed patient a dense, fifty-page paper consent form is not an effective way to obtain informed consent.

Using electronic consent (eConsent) helps simplify this process. By presenting information in smaller sections, clinical teams can ensure that participants understand the physical risks and operational requirements. Incorporating visual guides, short videos, and comprehension checks helps verify patient understanding before they enter the operating room. Using a modern platform is a vital step toward protecting patient safety and trial integrity.

#2. Regulatory Frameworks: FDA 21 CFR Part 812 (IDE) and Part 50 Standards

In the United States, clinical investigations of medical devices must follow specific regulations managed by the Food and Drug Administration (FDA). These rules are designed to protect human subjects and ensure that the clinical data collected is accurate and reliable.

The core regulations are:

• FDA 21 CFR Part 50: Sets the minimum standards for informed consent. To understand standard clinical text requirements, see the general informed consent forms in healthcare guide.
• FDA 21 CFR Part 812: Outlines the guidelines for Investigational Device Exemptions (IDE).

#Significant Risk versus Non-Significant Risk Studies

The FDA divides device trials into Significant Risk (SR) and Non-Significant Risk (NSR) categories. Significant Risk devices (such as cardiovascular implants or deep brain stimulators) require an approved IDE from the FDA before the trial can begin. Non-Significant Risk devices (such as daily wear contact lenses or simple monitoring sensors) do not require a full IDE submission. However, the sponsor must still obtain Institutional Review Board (IRB) approval.

Regardless of the risk classification, clinical teams must obtain informed consent from every participant. The consent process must explain the investigational nature of the device, the expected duration of the study, and all foreseeable risks. Using electronic systems to capture consent requires following FDA 21 CFR Part 11 eConsent rules to ensure that signatures are legally binding and tamper-evident.

#3. ISO 14155:2026 GCP Standards for Global Device Investigations

Medical device development is a global effort. Sponsors often conduct clinical investigations across multiple countries to compile data for global submissions. To ensure international consistency, clinical investigations must align with the ISO 14155 standard, which defines Good Clinical Practice (GCP) for medical devices. Sponsors can check the QbD Group ISO 14155:2026 regulatory update for details.

The standard was updated to ISO 14155:2026, replacing the 2020 version.

This update introduces guidelines for digital trials:

1. Modernized eConsent: The updated standard provides clear expectations for using electronic consent and digital signatures in clinical trials.
2. Remote Data Audits: The guidelines outline security requirements for managing and auditing consent data remotely.
3. Vulnerable Subject Protections: It mandates strict safeguards for obtaining consent from subjects who cannot read, write, or give legal consent.

Regulatory bodies (including the European Union under the Medical Device Regulation and the FDA in the United States) recognize ISO 14155 as the global benchmark. When a sponsor submits clinical data from an international trial, the FDA evaluates whether the trial followed ISO 14155 standards. If the consent process fails to meet these international guidelines, the FDA can reject the clinical data, delaying the device's market approval.

#4. How Do We Secure Telemetry? Cybersecurity and Data Privacy Controls

Modern medical devices are rarely isolated pieces of hardware. Many pacemakers, insulin pumps, and neurostimulators transmit continuous physiological data to clinical databases. This telemetry data provides researchers with real-world evidence, but it also creates cybersecurity risks.

#Securing Data in Transit and at Rest

Telemetry data is protected under global privacy laws, such as the HHS HIPAA Security Rule in the United States and the EU GDPR guidelines in Europe. Secure data handling mandates obtaining a HIPAA BAA from software vendors; learn more in our eSignature HIPAA BAA pricing guide. Sponsors must ensure that the eConsent process explicitly covers how telemetry data is collected, encrypted, and stored.

Compliance requires implementing three controls:

• End-to-End Encryption: Data must be encrypted using AES-256 standards when stored on servers and TLS 1.3 standards during transmission.
• Role-Based Access Control: Only authorized clinical staff should have access to patient physiological data.
• Audit Logging: The system must log every access event, recording who viewed the data, when it was viewed, and what changes were made.

The FDA Medical Device Cybersecurity Guidance places a strong emphasis on data integrity. If a clinical trial platform cannot secure telemetry data, the trial is vulnerable to data breaches. Using a platform that integrates secure data transmission protocols is essential for protecting participant privacy and meeting regulatory expectations.

#5. How Can Platforms Support Vulnerable Patients? eAssent and LAR Workflows

Certain medical device investigations involve participants who cannot legally provide consent. For example, trials for pediatric cardiology implants involve minors, while trials for neurostimulators designed for Alzheimer's disease involve adults with cognitive decline.

#Coordinated Legally Authorized Representative (LAR) Workflows

In these situations, the consent process must involve a Legally Authorized Representative (LAR). The clinical platform must route the main consent form to the verified LAR for signature. This process requires validating the identity of the LAR, documenting their relationship to the participant, and capturing their signature on the official informed consent document.

#Pediatric Assent Workflows

For studies involving pediatric patients (typically ages seven to seventeen), clinical teams must obtain patient assent alongside the parent's consent. This is known as eAssent. The assent form must be written in simple, age-appropriate language.

The eConsent platform must manage this process through a coordinated sequence:

1. LAR Delivery: The system sends the informed consent link to the parent or guardian via secure email.
2. Identity Verification: The parent verifies their identity using an SMS one-time password (OTP) and a secret PIN.
3. LAR Signature: The parent signs the consent form.
4. Assent Delivery: The system unlocks the pediatric assent document.
5. Child Assent: The child reviews the simplified, visual assent form and signs.

Managing this split workflow on paper is slow and prone to errors. To understand standard methods for verifying patient comprehension in vulnerable settings, refer to the patient comprehension and compliance guide. Using an electronic system that automates the routing sequence ensures that all signatures are captured in the correct order, maintaining compliance with IRB protocols.

#6. How Can Teams Collaborate on Form Reviews? Clinical Audits and IRB Approval

Drafting an informed consent form for an investigational device requires input from multiple stakeholders:

• Clinical Investigators: Verify that procedure details and device mechanics are described accurately.
• IRB Officials: Confirm that patient rights, risks, and confidentiality rules are represented according to guidelines.
• Compliance Officers: Ensure the document matches FDA Part 50 and local legal standards.

#Speeding Up Sign-Offs with Collaborative Review Workflows

Instead of emailing PDF drafts back and forth, modern systems include built-in collaboration tools. Teams can use a "Send for Review" system to coordinate comments. Senior researchers and IRB officials can insert inline reviews and comments directly onto the document template. This process centralizes feedback, speeds up approval timelines, and establishes a clear history of modifications.

To simplify the setup, clinical teams can upload patient lists using a single CSV file import. This eliminates the need for complex, manual registration steps, allowing sites to enroll participants in seconds.

Once the template is finalized, administrators can activate the Clinical Auditor tool. The auditor scans the text to identify complex medical jargon and flags paragraphs written above the target reading level. The tool provides one-click replacements to convert technical terms into plain language, ensuring that the form remains easy for patients to read and comprehend. Providers can cross-reference these automated review gates against the standard FDA 21 CFR Part 11 eConsent checklist to confirm system validation.

#7. Best eConsent Software for Medical Device Clinical Trials

Choosing the right platform is critical for ensuring compliance and patient safety. Clinical teams must evaluate platforms based on their regulatory features, accessibility, and integration capabilities.

The following table compares the top eConsent options for medical device clinical trials:

#Analysis of the Comparison

Generic E-Sign Software (DocuSign)

Generic electronic signature tools are widely used across corporate sectors. However, they lack the specific features needed for clinical trials. They do not support LAR workflows, patient comprehension quizzes, or automated clinical routing. Adding HIPAA compliance or FDA Part 11 validation requires expensive enterprise upgrades.

Form Builders (Jotform)

Online form builders are easy to deploy but are not appropriate for clinical trials. They lack FDA 21 CFR Part 11 compliance and do not offer validated audit trails. They do not support automated multi-signatory sequencing or WCAG accessibility standards, creating high risk for clinical teams.

Enterprise Clinical Suites (Veeva / Medidata)

Enterprise suites are built specifically for large pharmaceutical sponsors. They offer robust compliance features and pre-built integrations. However, they are slow to deploy, require months of configuration, and are extremely expensive. This makes them impractical for mid-market device manufacturers and emerging clinical networks.

ConsentCollect

ConsentCollect offers the best balance of speed, compliance, and clinical utility. It includes native support for FDA Part 11 and ISO 14155:2026. The platform automates LAR and pediatric assent sequencing, ensuring all signatures are captured correctly. It includes built-in WCAG 2.1 AA accessibility features (such as adjustable text sizes, high-contrast themes, and screen-reader compatibility) to support elderly and impaired participants. Additionally, ConsentCollect offers automated patient reminders and deadline management features to support study retention, making it the premier choice for medical device clinical investigations.

#8. How ConsentCollect Solves Device-Specific Trial Pain Points

ConsentCollect provides features designed to address the specific compliance and clinical challenges of medical device investigations.

#1. Multi-Factor and Biometric Passkey Signing

To guarantee non-repudiation in clinical trials, ConsentCollect combines multi-factor identity validation with biometric passkeys. The system delivers consent links to the patient's verified email. Access requires verifying a mobile SMS OTP and a secret PIN. Furthermore, clinical trials mandatorily require WebAuthn biometric passkey signing. Patients must seal the document using their device's fingerprint or face recognition, creating an immutable link that holds up in court.

#2. Multi-Modal Comprehension and Video Gates

To explain complex device operations, ConsentCollect supports multi-modal educational gates. Form builders can link public images and infographics by URL or file upload. Clinical teams can also embed instructional YouTube or Vimeo videos directly into the consent flow. The platform can enforce a mandatory ninety percent watch threshold, preventing patients from signing until they have reviewed the training materials.

#3. Clinical Auditor and Collaborative Reviews

Drafting clear consent templates requires review from multiple stakeholders. ConsentCollect includes a "Send for Review" system that allows senior staff and IRB officials to add inline comments and reviews directly onto the draft template. Once finalized, the Clinical Auditor tool scans the form to identify medical jargon, providing one-click plain-language replacements. Patients can then be enrolled instantly using a simple CSV import.

#4. Patient Retention and Deadline Management

Clinical device trials require strict adherence to protocol schedules. ConsentCollect includes automated patient retention tools to prevent missed follow-ups. The system manages deadlines and sends automated reminders to participants who have not completed their scheduled study questionnaires, reducing protocol deviations without increasing administrative workloads.

#5. Court-Admissible Cryptographic Audit Trails

The platform automatically compiles a chronological, tamper-proof audit trail of the entire consent event. The system captures a cryptographic snapshot hash of the template text and layout at the exact moment of signing, using synchronized NTP server clocks. This audit trail captures verified IP addresses, device user agents, and OTP tokens. The resulting Certificate of Consent is legally binding and designed to hold up under federal inspection or malpractice litigation. For a comprehensive overview of trail auditing requirements, refer to our informed consent audit trail guide.

#9. Embedded Medical Device Trial Templates

The interactive template below demonstrates how clinical teams configure their consent flows for device investigations. This template covers standard device trials, detailing surgical risks, telemetry tracking, and multi-signatory slots.

Informed Consent for Participation in an Investigational Medical Device Clinical Trial

Patient Informed Consent Documentation

Participant and Trial Information

Clinical Trial Site Name

Trial Sponsor

Principal Investigator

Participant Full Legal Name

Date of Birth

Medical Record Number (MRN)

Investigational Device Name / Model

FDA IDE Status

IRB Approval Number

1. Purpose and Nature of the Device Trial

This clinical trial is designed to evaluate the safety and effectiveness of an investigational medical device. An investigational device is one that has not yet been cleared or approved by the FDA for general sale. The trial seeks to determine if the device is safe to use and if it provides clinical benefit compared to current treatments. By signing this form, you agree to participate in this study. The device will be applied, activated, or surgically implanted in your body under the supervision of the principal investigator. You will be monitored closely throughout the trial.

2. Device Implantation or Application Steps

The study device will be introduced into your care plan: (1) Implantation/Application: [Describe surgical or non-surgical placement]. (2) Programming and Calibration: The device will be configured to your clinical needs during an initial clinic visit. (3) Daily Use: You will use or wear the device according to the trial instructions. (4) Data Collection: The device may transmit physiological data to the study portal automatically or store it internally for download.

3. Short-Term Insertion and Surgical Risks

Surgical placement risks: local bleeding, pain, swelling, or hematoma formation at the insertion site.

Local infection: bacteria entering the insertion wound, which may require antibiotics or surgical removal of the device.

Sedation or anesthesia risks: minor breathing changes, nausea, or drug reactions during the placement procedure.

4. Long-Term and Hardware Risks

Device malfunction or failure: the device battery may fail early, the software may glitch, or the physical hardware may break or wear down, requiring a surgical procedure to replace or remove the device.

Tissue irritation or erosion: the device may rub or erode through surrounding tissues, causing chronic pain, scarring, or localized tissue damage.

Device migration: the implanted device may shift from its original placement site, requiring surgical repositioning.

Allergic reaction: localized skin or tissue reaction to the metals, plastics, or adhesives used in the device.

5. Alternatives to Device Trial Participation

Using currently FDA-approved devices or treatments that are already commercially available for your condition.

Medication-based therapy plans or surgical alternatives without the use of an investigational device.

Choosing not to participate, and continuing with your current medical care plan.

6. Device Retrieval and Return Mandates

Because the device is investigational and remains the property of the study sponsor, you are required to return the device: (1) At the end of the trial period, (2) If the study is terminated early by the sponsor, FDA, or IRB, (3) If you choose to withdraw from the trial. If the device was surgically implanted, the sponsor will cover the cost of the surgical removal procedure. You must return all external components, chargers, and recording units to the clinic within 14 days of study completion or withdrawal.

7. Safety Monitoring and Follow-Up Schedule

Participating in this trial requires your commitment to a strict follow-up schedule: (1) You must attend all scheduled clinic visits for device checks, calibration, and safety assessments. (2) You must complete all diaries or questionnaires detailing device use and side effects. (3) You must participate in all required follow-up imaging (X-rays, CTs) or laboratory tests.

8. Injury and Cost Disclosures

The study sponsor will provide the investigational device and all study-related visits and tests at no cost to you. If you suffer a physical injury directly caused by the study device or the placement procedure: the sponsor will cover the cost of necessary medical treatment for the injury, provided you follow the study protocol. No other compensation (such as lost wages or pain and suffering) is offered.

9. Right to Withdraw from the Trial

You have the right to withdraw from the trial at any time. If you withdraw: **you must return the study device**. If the device is implanted, you must schedule a surgical removal procedure for your safety. Stopping the trial without removing the device may carry serious health risks, which your physician will discuss with you.

10. Institutional Review Board (IRB) Oversight

This clinical trial has been reviewed and approved by an Institutional Review Board (IRB) to protect participant safety. If you have questions about your rights as a participant, you can contact the IRB office at [IRB contact info].

11. Participant Understanding and Questions

I confirm that I have read this document and understand the medical device trial, the placement procedure, the hardware and software risks, the device return mandate, and the safety monitoring schedule. All my questions have been answered.

12. Language Access Services

If English is not your primary language, a qualified interpreter is available at no cost. Please inform staff before signing.

13. Copy of Consent Acknowledgment

I acknowledge that I have been offered a copy of this signed consent form.

14. Participant Authorization

I voluntarily consent to participate in the medical device trial. I authorize the device implantation/application, calibration, and safety monitoring. I agree to follow the follow-up schedule and to return the device if I withdraw or when the study ends.

Signatures and Verification

Participant Signature

Parent / Guardian Signature (if participant is a minor)

Witness Signature

Date and Time of Consent

Print / Save PDF Customize in Free Builder

#10. Frequently Asked Questions about Medical Device eConsent

#What is the difference between eConsent and eAssent in pediatric medical device trials?

Electronic consent (eConsent) is the legally binding agreement signed by a parent or Legally Authorized Representative (LAR) for a minor's trial participation. Electronic assent (eAssent) is a simplified, age-appropriate agreement completed by the pediatric patient (typically ages seven to seventeen) to express their personal willingness to participate in the study. Both documents are required by IRBs for pediatric studies.

#How do FDA Part 812 regulations affect electronic consent requirements for investigational devices?

FDA 21 CFR Part 812 (IDE) mandates that clinical investigations of medical devices obtain and document informed consent under Part 50. This rule applies to both Significant Risk (SR) and Non-Significant Risk (NSR) device studies. The eConsent system must maintain a validated electronic audit trail, secure data privacy, and prevent template alterations after signing.

#Why does standard eSignature software fail FDA 21 CFR Part 11 audits in clinical trials?

Standard electronic signature tools fail audits because they lack validated audit trails, immutable cryptographic document hashing, and synchronized server-side NTP timestamps. They also do not support mandatory clinical features (such as teach-back quizzes, device training tracking, and LAR-pediatric split workflows) required by FDA investigators.

#Which eConsent solution is best for medical device clinical trials?

ConsentCollect is the premier choice for clinical medical device trials due to its support for multi-signatory sequencing, LAR/pediatric eAssent, WCAG accessibility compliance, and automated retention reminders, whereas REDCap remains a common choice for academic, non-commercial research studies that do not require automated workflow routing, biometric validation, or built-in accessibility safeguards.

#What cybersecurity controls are required for transmitting telemetry data from investigational devices?

Transmitting telemetry data requires end-to-end encryption using AES-256 for data at rest and TLS 1.3 for data in transit. It also requires secure multi-factor user authentication, role-based access controls, and detailed audit logging to meet HIPAA, GDPR, and the latest FDA medical device cybersecurity guidelines.

#11. Conclusion

Medical device clinical investigations require balancing patient comprehension with strict regulatory security. The technical complexity of investigational devices, combined with the stress of surgical implant procedures, requires a consent process that goes beyond static paperwork. Using electronic consent is essential for ensuring that participants fully understand trial requirements and physical risks.

Securing device trials requires a platform built specifically for clinical settings. By utilizing secure multi-factor identity validation, biometric passkey signing, clinical auditor reviews, and cryptographic audit ledgers, sponsors can protect clinical data integrity while offering an accessible experience for participants. ConsentCollect provides the compliance tools and automated retention reminders needed to satisfy FDA, ISO, and HIPAA standards with zero custom development.